A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors

In this phase 1 open-label study, we assessed the relative bioavailability of a prototype tablet formulation of TAK-931, a cell division cycle 7 kinase inhibitor, in reference to the current powder-in-capsule (PIC) formulation in patients with advanced solid tumors for whom no effective standard tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Steeghs, Neeltje, Pruis, Melinda, van Herpen, Carla, Lu, Vickie, Redman, John, Zhou, Xiaofei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030390/
https://www.ncbi.nlm.nih.gov/pubmed/36409435
http://dx.doi.org/10.1007/s10637-022-01318-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030390/
https://www.ncbi.nlm.nih.gov/pubmed/36409435
http://dx.doi.org/10.1007/s10637-022-01318-3

Ejemplares similares